



Jumonji Domain-Containing Proteins in Cancer Progression

Guest Editors:

Prof. Dr. Sangphil Oh

Stephenson Cancer Center, The
University of Oklahoma Health
Sciences Center, Oklahoma City,
OK 73104, USA

Dr. William Berry

Department of Surgery,
University of Oklahoma Health
Sciences Center, Oklahoma City,
OK, USA

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editors

Cancer cell growth is largely driven by the silencing of tumor-suppressor genes and/or the expression of oncogenes. Histone lysine methylation was first discovered in the 1960s which gave rise to the study of enzymes named histone methyltransferases which have the ability to methylate specific lysine residues on histones to control gene transcription. It was long believed that lysine methylation was irreversible, until 2004 when the first histone demethylase was discovered. Since that time, Jumonji C Domain-Containing (JMJD) proteins were discovered which function to remove methyl groups from lysine and arginine residues on histones H3 and H4 to regulate gene expression. Similar to histone methyltransferases. Therefore, it is important to further determine whether JMJD proteins are potential therapeutic targets.

We would like to invite scientists to submit manuscripts focusing on the JMJD proteins in cancer progression. Contributions to this Special Issue will cover in the format of reviews, original research articles, communications, and concept papers.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and
Molecular Medicine, Faculty of
Health and Medical Sciences,
University of Copenhagen,
Blegdamsvej 3C, DK-2200
Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer
Science, Virginia Commonwealth
University, Richmond, VA 23284,
USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

Contact Us

Biomolecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
X@Biomol_MDPI